Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470
Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular
hypertension or open-angle glaucoma. In the adaptive dose selection phase of the trial,
subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%)
or to latanoprost 0.005%. Following the selection of one dose of NCX 470, subjects will be
randomized in a 1:1 ratio to the chosen dose of NCX 470 or to latanoprost 0.005%.